Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Source: Clinical Resources From inPractice HIV

Module

Paul E. Sax, MD, discusses issues to be considered in selecting an initial antiretroviral regimen as well as considerations for special patient settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate best practices in the management of first-line antiretroviral therapy

Topics covered include:

  • Introduction
  • Antiretroviral Treatment Guidelines for First-line Therapy in Adult Patients
  • Pretherapy Antiretroviral Resistance Testing
  • Clinical Trials of NNRTI-Based vs PI-Based Therapy
  • Clinical Trials of INSTI-Based vs NNRTI-Based Therapy
  • Clinical Trials of INSTI-Based vs Boosted PI-Based Therapy
  • Choosing Among the Integrase Inhibitors for First-line Therapy
  • Choosing Among the NNRTIs for First-line Therapy
  • Choosing Among the Boosted PIs for First-line Therapy
  • Selection of the NRTI Pair
  • Maraviroc-Based Initial Therapy
  • NRTI-Limiting Approaches in Initial Therapy
  • Recommendations for Special Situations
 

Program Directors

  • Joseph J. Eron, Jr.
    MD
    Daniel R. Kuritzkes
    MD
    Kathleen E. Squires
    MD
    Joel E. Gallant
    MD, MPH

Faculty

  • Paul E. Sax
    MD
  • Release Date:
    January 20, 2017

Information on this Educational Activity

Program Directors

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and ViiV; consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche Molecular Systems, Tibotec/Janssen, and ViiV; and has served on the data and safety monitoring board for TaiMed.

 

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Bionor, Gilead Sciences, GlaxoSmithKline, InnaVirVax, Janssen, Merck, Oncolys, Teva, ViiV, and ViroStatics; fees for non-CME/CE services from Merck; and funds for research support from Gilead Sciences.

 

Kathleen E. Squires, MD

W. Paul and Ida H. Havens Professor of Infectious Diseases
Director,
Division of Infectious Diseases
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania

Kathleen E. Squires, MD, has disclosed that she has served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; has served on advisory boards for marketing purposes for Gilead Sciences and Janssen; and has received funds for research support from Gilead Sciences.

 

Joel E. Gallant, MD, MPH

Medical Director of Specialty Services
Southwest CARE Center
Santa Fe, New Mexico
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Janssen, Theratechnologies, and ViiV/GlaxoSmithKline and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sangamo, and ViiV/GlaxoSmithKline.

 

Faculty

Paul E. Sax, MD


Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and funds for research support from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline/ViiV.
 

Staff

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has nothing to disclose with regard to commercial interests.
 

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has nothing to disclose with regard to commercial interests.
 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.
 

  • Choosing Statins for Patients With Dyslipidemia and Elevated CVD Risk

    David A. Wohl MD - 6/1/2017    1 comment / Last Comment: 6/16/2017
    Which statins should be avoided in patients receiving boosted ART regimens?
  • Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR

    Eric S. Daar MD - 6/21/2017    
    What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?
  • Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data

    Eric S. Daar MD - 6/21/2017    
    For a newly-diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
  • ART Switch for Comorbidities in a Middle-Aged Black Woman

    Lisa Hightow-Weidman MD, MPH - 5/12/2017    1 comment / Last Comment: 6/16/2017
    One-tablet regimens may not always be the best choice of ART, but the best choice is always the one the patient is willing to take.
  • Selecting ART for an Aging Patient With Multiple Comorbidities and Potential Drug–Drug Interactions

    David A. Wohl MD - 5/31/2017    
    In an older patient managing hypertension, reactive airways disease, and moderate renal insufficiency, what ART regimen would you recommend?